This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Oyamada, N. Articles by Nakao, K. Search for Related Content PubMed PubMed Citation Articles by Oyamada, N. Articles by Nakao, K. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB SPIRONOLACTONE

The Role of Mineralocorticoid Receptor Expression in Brain Remodeling after Cerebral Ischemia

Department of Medicine and Clinical Science (N.O., M.S., K.M., K.P., D.T., M.I., T.S., H.T., Y.F., N.T., K.N.), Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto 606-8507, Japan; and Department of Internal Medicine (H.I.), Keio University School of Medicine, Shinjuku-ku Tokyo 160-8582, Japan

Address all correspondence and requests for reprints to: Masakatsu Sone, Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan. E-mail: sonemasa{at}kuhp.kyoto-u.ac.jp.

Mineralocorticoid receptors (MRs) are classically known to be expressed in the distal collecting duct of the kidney. Recently it was reported that MR is identified in the heart and vasculature. Although MR expression is also found in the brain, it is restricted to the hippocampus and cerebral cortex under normal condition, and the role played by MRs in brain remodeling after cerebral ischemia remains unclear. In the present study, we used the mouse 20-min middle cerebral artery occlusion model to examine the time course of MR expression and activity in the ischemic brain. We found that MR-positive cells remarkably increased in the ischemic striatum, in which MR expression is not observed under normal conditions, during the acute and, especially, subacute phases after stroke and that the majority of MR-expressing cells were astrocytes that migrated to the ischemic core. Treatment with the MR antagonist spironolactone markedly suppressed superoxide production within the infarct area during this period. Quantitative real-time RT-PCR revealed that spironolactone stimulated the expression of neuroprotective or angiogenic factors, such as basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF), whereas immunohistochemical analysis showed astrocytes to be cells expressing bFGF and VEGF. Thereby the incidence of apoptosis was reduced. The up-regulated bFGF and VEGF expression also appeared to promote endogenous angiogenesis and blood flow within the infarct area and to increase the number of neuroblasts migrating toward the ischemic striatum. By these beneficial effects, the infarct volume was significantly reduced in spironolactone-treated mice. Spironolactone may thus provide therapeutic neuroprotective effects in the ischemic brain after stroke.

This article has been cited by other articles:

				A. M. Dorrance Stroke Therapy: Is Spironolactone the Holy Grail? Endocrinology, August 1, 2008; 149(8): 3761 - 3763. [Full Text] [PDF]